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Abstract Fructose-1,6-bisphosphatase (FBPase) deficiency is a rare inborn error of 
metabolism affecting gluconeogenesis caused by FBP1 gene mutations. It could 
be more fatal to infants and children when glycogen reserves are insufficient. 
A 4-year-old girl was admitted with complex febrile convulsion. Initial laboratory 
results showed hypoglycemia, metabolic acidosis, and hyperlactatemia. Plasma 
amino acid and urine organic acid analyses showed increased levels of alanine 
and tricarboxylic acid cycle intermediates. However, she had similar clinical fea-
tures, including confusion under severe hypoglycemia, two additional times over 
6 months. Correct diagnosis could not be made because of nonspecific symptoms, 
and mitochondrial disorder was initially suspected. Clinical exome sequencing 
was performed, and compound heterozygous mutations of c.960_961insG and 
c.490G>A (p. Ser321ValfsTer13 and p. Gly164Ser) in the FBP1 gene were iden-
tified. This is the first Korean pediatric case of FBPase deficiency that initially 
presented with neurologic clinical features. Despite its very low prevalence in 
Far-East Asian countries, FBPase deficiency should be considered in children with 
repeated clinical features of metabolic acidosis with hypoglycemia.
INTRODUCTION
FBPase is a key enzyme in gluconeogenesis that 
converts fructose 1,6-bisphosphate to fructose 
6-phosphate and inorganic phosphate. FBPase 
deficiency (OMIM #229700) is caused by muta-
tions of the FBP1 gene in an autosomal recessive 
manner (Baker & Winegrad, 1970). This disorder 
may cause life-threatening episodes of severe met-
abolic acidosis and hypoglycemia. Episodes are 
triggered by fasting, illness, and fever. The symp-
toms of affected individuals are nonspecific and 
easily misdiagnosed as mitochondrial disorders 
or other metabolic diseases (Kikawa et al. 1997; 
Santer et al. 2016). 
The patient presented with neurologic features 
described in this report had repeated episodes of 
hypoglycemia and metabolic acidosis. Clinical 
exome sequencing (CES) was performed to deter-
mine the cause of metabolic conditions, and com-
pound heterozygous mutations in the FBP1 gene 
were identified. 
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CASE REPORT
A 4-year-old girl was admitted for complex febrile con-
vulsions with hypoglycemia and metabolic acidosis. She 
was born at term after an uneventful pregnancy and 
delivery. At the time of admission, her blood sugar was 
too low to be checked, and she was in a semi-comatose 
state. Her insulin level was low, and acylcarnitine was 
within the normal limit. Her initial laboratory results 
indicated metabolic acidosis, hypoglycemia, hyperlac-
tatemia, and hyperuricemia. Serum amino acid analysis 
showed an increased alanine level, and urine organic 
acid analysis revealed elevated tricarboxylic acid cycle 
intermediate levels. In addition, the blood lactate-to-
pyruvate molar ratio (lactate, 6.3 mmol/L: pyruvate, 0.2 
mmol/L; 31>25) increased, as often shown in impaired 
oxygen phosphorylation. She experienced three more 
episodes of febrile convulsions within 1 day and was 
given antiepileptic therapy. Electroencephalography 
(EEG) initially showed more increased spike discharge 
and decreased frequency with slow background on the 
right hemisphere. After initiation of glucose infusion, 
her blood sugar returned to normal. EEG normaliza-
tion was reported, and her neurologic symptoms were 
favorable. Brain magnetic resonance imaging showed 
no abnormal findings.
After several months, she presented abdominal pain 
with fever after more than 8 hours of fasting. Abdomi-
nal examination revealed no hepatomegaly as shown 
in glycogen storage disorder. Eating candies contain-
ing sorbitol caused her vomiting to worsen. Along 
with metabolic acidosis (pH, 7.176; base excess, −18.5 
mmol/L) and hypoglycemia, she had severe gastro-
enteritis symptoms that caused lethargy and mental 
change. Clinical and laboratory data are presented in 
Table 1. 
CES was performed to confirm the diagnosis of 
repeated metabolic ketoacidosis, and compound het-
erozygous mutations of c.960_961insG and c.490G>A 
(p. Ser321ValfsTer13 and p. Gly164Ser) in the FBP1 
Tab. 1. Clinical and laboratory information for each attack.
1st event 2nd event 3rd event 4th event
Age at each event 4yr 5month 4yr 9month 4yr 11month 5yr 2month
Symptoms for hospitalization 
due to hypoglycemia
Mental change 
(semicoma),
Seizure,
Fever,
Vomiting
Fasting status,
Fever,
Vomiting,
Abdominal pain
Fever,
Vomiting,
Abdominal pain
Mental change
(Drowsiness),
Vomiting
Blood gas analysis
   pH (7.32~7.38) 7.264 7.176 7.179 7.254
   pCO2 (38~50mmHg) 33.0 19.0 28.8 27.3
   HCO3 (22~29mM) 15.1 7.1 10.8 12.2
   BE (-5~3mM) -10.2 -18.5 -15.5 -12.8
Biochemical evaluation
   Glucose (70-110mg/dL) Low(uncheckable)
Low
(uncheckable) <7 8
   Urea (7~17mg/dL) 15.6 51.9 16.1 22.3
   Creatine(0.21~0.53mg/dL) 0.34 0.69 0.43 0.35
   Uric acid (2.5~5.9mg/dL) 8.4 18.7 10.5 10.0
   AST (13.0~34.0IU/L) 162 71 45 60
   ALT (5.0~46.0IU/L) 67 72 18 22
   Albumin (3.8~5.4 g/dL) 4.4 4.8 4.8 4.8
Hormone evaluation
   Insulin (1.0~10.7uU/mL) <0.20 <0.20 <0.20
   Cortisol (6.7~22.6ug/dL) 37.0 37.5 34.3
   Growth hormone (0~9.5ng/mL) 0.62 1.90 1.00
   IGF-1 (30.1~252.2ng/mL) 61.4 68.7 88.0
Metabolic evaluation
   Lactate (0.5~2.2mmol/L) 6.3 4.2 5.1 7.2
   Ketone(urine) 2+ 3+ 2+ 2+
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gene were identified. Variants were verified by Sanger 
sequencing (Figure 1). After the diagnosis of FBPase 
deficiency, the patient was instructed to avoid pro-
longed fasting and to restrict her dietary intake of fruc-
tose and sucrose. She did not experience any clinical 
episodes during the follow-up period. 
DISCUSSION AND CONCLUSION
The estimated incidence of FBPase deficiency is less 
than 1 in 900,000 individuals; so far, only one case of 
an adult who had a compound heterozygote for G164S 
and 838delT has been reported in Korea (Moon et al. 
2011; Santer et al. 2016). 
Previous studies have shown that prolonged hypo-
glycemia can lead to energy failure and interruptions 
of many critical cellular activities. The brain utilizes 
25% of the body’s glucose owing to its high metabolic 
rate, and it requires a continuous supply of glucose 
because it does not produce glucose intrinsically and 
only contains a very limited store of glycogen. During 
hypoglycemia, glutamate and aspartate increase in the 
tissue because of truncation of the tricarboxylic acid 
cycle and initially affects sodium and water influx, 
which causes cellular edema (Neil & Hemmen, 2011). 
The hypoglycemia can manifest as seizures, stroke-like 
episodes, cognitive dysfunction, and coma. 
Because FBPase deficiency is very rare, nonspecific 
symptoms of the disease can be easily misdiagnosed as 
other metabolic diseases such as respiratory chain dis-
orders or glycogen storage diseases causing hypogly-
cemia and lactic acidosis (Lebigot et al. 2015; Li et al. 
2017). Our patient’s neurological clinical features and 
increased blood lactate-to-pyruvate molar ratio ini-
tially caused suspicion of mitochondrial disease. Most 
FBPase deficiency patients initially present during 
the first 2 years of life. However, some patients show 
accompanying neurologic symptoms after a period of 
clinical silence, especially infants or young children 
who are first referred to the neurology clinic and are 
often suspected of other disorders. 
The diagnosis of FBPase deficiency is established 
by mutation analysis of the FBP1 gene and measure-
ment of FBPase activity. The sensitivity of FBPase 
activity measurement remains relatively low, and this 
diagnostic procedure is generally considered invasive 
because of the use of liver biopsy (Asberg et al. 2010; 
Li et al. 2017). However, CES using a next-generation 
sequencing technique is non-invasive and particularly 
useful for molecular diagnosis of complex metabolic 
diseases and other rare genetic conditions at the same 
time.
Hypoglycemia in patients with FBPase deficiency 
should be treated properly by glucose infusion. Glu-
cagon injections may be ineffective and provoke the 
accumulation of gluconeogenic substrates such as lac-
tate, alanine, and glycerol. Intravenous administration 
of glycerol or fructose solution for treatment of brain 
edema should not be used in any patients with hypo-
glycemia-induced neurologic symptom before evalu-
ation of FBPase deficiency (Hasegawa et al. 2003). 
Therefore, an accurate diagnosis is important for 
proper management and prevention of complications 
of the disease. Early diagnosis of FBPase deficiency 
and simple interventional measures such as avoidance 
of prolonged fasting in febrile illness and restriction of 
dietary fructose and sucrose could reduce the risk of 
metabolic decompensation.
Each variant identified in this patient had been 
previously reported as a pathogenic allele (Kikawa 
et al. 1997; Li et al. 2017). The frameshift mutation 
(c.960_961insG) was known as the most common 
mutation in Japan and was identified in a Korean 
patient for the first time (Herzog et al. 2001; Kikawa 
et al. 1997). Because of the small number of patients, 
it is difficult to suggest that any ethnic background 
has a high prevalence of this mutation. However, 
a  recent study indicated that ethnicity might affect 
the spectrum of mutations (Herzog et al. 2001; Santer 
et al. 2016). In addition, another missense mutation, 
c.490G>A, has also been previously described in Asian 
patients (Santer et al. 2016).
In summary, we reported the first pediatric case of 
FBPase deficiency diagnosed using CES in a 4-year-
old Korean girl who presented with initial symptom of 
complex febrile convulsions. Because of the rarity of 
FBPase deficiency, it can be easily misdiagnosed and 
can lead to unfavorable outcomes. FBPase deficiency 
should be in the differential diagnosis when infants 
and children have repeated clinical features of meta-
bolic acidosis with hypoglycemia. It would be inter-
esting to determine whether FBPase mutations have 
a founder effect among Asian populations.
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Fig. 1. Missense mutation c.490G>A in exon 4 predictably leading to the exchange of glycine 
with serine at codon 164, and insertion mutation 960_961insG predictably leading to frame 
shift and termination of protein translation (top). Both mutations were confirmed by Sanger 
sequencing (bottom). 
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